MB-SDWG@EC2702A

ONE MEDIA GROUP

TOUYUN BIOTECH

ALCO HOLDINGS

TI CLOUD

PETRO-KING

CHINA RISUN GP

GOLDEN THROAT

CH TIANBAO GP

CHAMPION TECH

JINYUAN HCHEM

159883

562600

01066

159898

Shandong Weigao Group Medical Polymer Co. Ltd. held an Extraordinary General Meeting on February 12, 2026, where the resolution outlined in the meeting notice was approved. This information was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

Reuters

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

WEIGAO GROUP

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Shandong Weigao Group Medical Polymer Co. Ltd. Held Extraordinary General Meeting

Shandong Weigao Group Medical Polymer Co. Ltd. repurchased 120,000 shares on February 11, 2026, at an average price of HKD 5.31 per share, totaling approximately HKD 637,200. The shares are held as treasury shares. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 120,000 shares for HKD 637,200

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 61,600 shares at a price of 5.26 HKD per share, totaling approximately 323,984 HKD. The shares will be held as treasury shares.

Shandong Weigao Group Medical Polymer Co. Ltd. repurchases 61,600 shares for HKD 323,984

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 120,000 shares at HKD 5.28 each, totaling approximately HKD 634,000. This transaction is part of their treasury shares acquisition.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 120,000 shares for HKD 634,000 at HKD 5.28 each

159316

512290

159570

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

SKB BIO-B

ChinaAMC SSE STAR Biology and Medicine ETF

KELUN PHARMA

HENLIUS

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

HYGEIA HEALTH

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

WuXi AppTec

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

WUXI XDC

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI APPTEC

Bosera Hang Seng SCHK Innovative Drug Select ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 100,000 shares at HKD 5.19 each, totaling approximately HKD 519,400. The shares will be held as treasury shares. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 100,000 shares for HKD 519,400

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 140,000 shares at a price of HKD 5.05 each, totaling approximately HKD 706,600. The shares will be held as treasury shares.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 140,000 shares for HKD 706,600 at HKD 5.05 each

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 220,000 shares at an average price of HKD 4.99 each, totaling approximately HKD 1,097,000. The shares will be held as treasury shares. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 220,000 shares for HKD 1,097,000 at HKD 4.99 each

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 1,112,000 shares at an average price of HKD 5.05 each, totaling approximately HKD 5,616,580. The shares will be held as treasury shares following the transaction.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 1,112,000 shares at HKD 5.05 each for HKD 5,616,580

Shandong Weigao Group Medical Polymer (SEHK:1066) has scheduled an Extraordinary General Meeting for February 12, 2026, to seek shareholder approval for significant structural changes. The company has seen a 30-day share price return of 5.41% and a 1-year total return of 13.02%, but a 3-year loss of 56.58%. Currently trading at HK$5.26, the stock has a P/E of 10.8x, below industry averages, suggesting it may be undervalued. A DCF analysis estimates a fair value of HK$14.21 per share, indicating potential upside, but investor sentiment remains cautious due to past performance and upcoming changes.

Simplywall

A Look At Shandong Weigao Group Medical Polymer’s Valuation As Major EGM Transactions Are Proposed

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 160,000 shares at an average price of HKD 5.24 each, totaling approximately HKD 838,600. The shares will be held as treasury shares. This announcement was published via the Hong Kong Stock Exchange.

Shandong Weigao Group Medical Polymer Co. Ltd. Buys Back 160,000 Shares for HKD 838,600 at HKD 5.24 Each

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 160,000 shares at HKD 5.19 each, totaling approximately HKD 830,200. The shares will be held as treasury shares. This information was published via the Hong Kong Stock Exchange.

Shandong Weigao Group Medical Polymer Co. Ltd. repurchases 160,000 shares for HKD 830,200 at HKD 5.19 each

Shandong Weigao Group Medical Polymer Co. Ltd. has repurchased 260,000 shares at HKD 5.14 each, totaling approximately HKD 1,337,400. The shares will be held as treasury shares. This information was published via the Issuer Information Service by the Hong Kong Stock Exchange.

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 260,000 shares for HKD 1,337,400 at HKD 5.14 each

MB-SDWG@EC2702A(27079.HK)

Shandong Weigao Group Medical Polymer Co. Ltd. Held Extraordinary General Meeting

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 120,000 shares for HKD 637,200

Shandong Weigao Group Medical Polymer Co. Ltd. repurchases 61,600 shares for HKD 323,984

Shandong Weigao Group Medical Polymer Co. Ltd. buys back 120,000 shares for HKD 634,000 at HKD 5.28 each

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies